AI will cure cancer in our lifetime, claims boss of UK chip giant

The boss of the biggest UK-headquartered tech firm has said that artificial intelligence will find a cure for cancer that ...
STAT

In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. AstraZeneca on Friday detailed the ...
FierceBiotech

AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda

AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune checkpoint ...
Becker's Hospital Review

How AstraZeneca’s $400B Bristol Myers deal fell apart

AstraZeneca’s board scrapped merger talks with Bristol Myers Squibb on Aug. 3, days after reports emerged that the companies were discussing a roughly $400 billion tie-up, according to an Aug. 11 ...
NJBIZ

AstraZeneca, BMS not pursuing merger talks: Reuters

After earlier reports that AstraZeneca and New Jersey-based competitor Bristol Myers Squibb were exploring a mega merger, sources told Reuters the pharmaceutical giants will not consider a potential ...
Wall Street Journal

Deal or No Deal, AstraZeneca Stock Is a Bargain

Few big-pharma bosses enjoy a stronger reputation on Wall Street than AstraZeneca’s AZN0.30%increase; up pointing triangle chief executive, Pascal Soriot. So the idea that he would stake his company’s ...
CNBC

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb's U.S.-centric business, but at the cost of slower growth and ...
Seeking Alpha

Bristol-Myers Squibb, AstraZeneca deal talks remain active - report

AstraZeneca's (AZN) deal talks with Bristol-Myers Squibb (BMY) remain active, according to a Semafor report on Tuesday. Shares of Bristol-Myers edged higher by 0.3%. AstraZeneca fell 1.2%. The latest ...
Wall Street Journal

AstraZeneca Shares Drop, Bristol Myers Squibb’s Climb After Merger Talks Reports

AstraZeneca AZN-0.31%decrease; down pointing triangle shares fell sharply and Bristol Myers Squibb’s BMY-0.58%decrease; down pointing triangle climbed, after media reports that the two drugmakers held ...
New York Post

AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report

UK drugmaker AstraZeneca has been exploring a deal to combine with US rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter. The deal could create ...
techtimes

AstraZeneca Targets $400B Bristol Myers Squibb Merger Twelve Years After Spurning Pfizer

AstraZeneca — the British pharmaceutical giant that famously rebuffed a $118 billion hostile takeover from Pfizer in 2014 by pledging to remain fiercely independent — is now reportedly pursuing a ...